269 related articles for article (PubMed ID: 27100411)
1. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
[TBL] [Abstract][Full Text] [Related]
3. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
4. Development and external validation of a nomogram for predicting the conditional probability of survival after D2 lymphadenectomy for gastric cancer: A multicentre study.
Chen QY; Zhong Q; Wang W; Desiderio J; Liu ZY; Xie JW; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Li P; Zheng CH; Zhou ZW; Parisi A; Huang CM
Eur J Surg Oncol; 2019 Oct; 45(10):1934-1942. PubMed ID: 31027946
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
6. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
[TBL] [Abstract][Full Text] [Related]
8. The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China.
Liu K; Chen XZ; Zhang YC; Zhang WH; Chen XL; Sun LF; Yang K; Zhang B; Zhou ZG; Hu JK
Surgery; 2021 Feb; 169(2):426-435. PubMed ID: 32950240
[TBL] [Abstract][Full Text] [Related]
9. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
10. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
[TBL] [Abstract][Full Text] [Related]
11. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer.
Wang ZX; Li GX; Zhou ZW; Huang ZP; Wang F; Xu RH
Br J Surg; 2017 Aug; 104(9):1226-1234. PubMed ID: 28449182
[TBL] [Abstract][Full Text] [Related]
12. A comparative analysis on clinical efficacy of FOLFOX6 regimen and DCF regimen as neoadjuvant chemotherapy combined with radical gastrectomy in treating advanced gastric cancer.
Tai Q; Shao H; Liu Y; Li E; Zhao R
J BUON; 2019; 24(5):2006-2012. PubMed ID: 31786868
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
[TBL] [Abstract][Full Text] [Related]
14. The effects of laparoscopic spleen-preserving splenic hilar lymphadenectomy on the surgical outcome of proximal gastric cancer: a propensity score-matched, case-control study.
Huang CM; Chen T; Lin JX; Chen QY; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Cao LL; Lin M; Tu RH
Surg Endosc; 2017 Mar; 31(3):1383-1392. PubMed ID: 27450211
[TBL] [Abstract][Full Text] [Related]
15. Application value of nomogram and prognostic factors of gastric cancer patients who underwent D2 radical lymphadenectomy.
Mu GC; Huang Y; Liu ZM; Wu XH; Qin XG; Chen ZB
BMC Gastroenterol; 2019 Nov; 19(1):188. PubMed ID: 31729975
[TBL] [Abstract][Full Text] [Related]
16. Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer.
Jiang Y; Li T; Liang X; Hu Y; Huang L; Liao Z; Zhao L; Han Z; Zhu S; Wang M; Xu Y; Qi X; Liu H; Yang Y; Yu J; Liu W; Cai S; Li G
JAMA Surg; 2017 Jul; 152(7):e171087. PubMed ID: 28538950
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience.
Ghidini M; Donida BM; Totaro L; Ratti M; Pizzo C; Benzoni I; Lomiento D; Aldighieri F; Toppo L; Ranieri V; Senti C; Tanzi G; Martinotti M; Passalacqua R; Rovatti M; Tomasello G
Clin Transl Oncol; 2020 Jul; 22(7):1004-1012. PubMed ID: 31599376
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
Lu W; Zeng X; Li N; Liu H
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
[TBL] [Abstract][Full Text] [Related]
20. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
